Katrien L. A. Quintelier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Katrien L. A. Quintelier has a total of 173 co-authors. Here are the top co-authors by number of shared publications:
- Sofie Van Gassen
Data Mining and Modeling for Biomedicine VIB Center for Inflammation Research Ghent Belgium
19 shared publications - Yvan Saeys
Data Mining and Modelling for Biomedicine group, VIB Center for Inflammation Research, Ghent, Belgium
19 shared publications - Joachim G. J. V. Aerts
Department of Respiratory Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands
15 shared publications - Ruth Seurinck
Ghent University 1 Department of Mathematics, Computer Science and Statistics Ghent, Belgium
15 shared publications - Christianne Groeneveldt
Erasmus University Medical Center 1 Department of Pulmonary Medicine Rotterdam, the Netherlands
14 shared publications - Cor H. J. Lamers
Department of Medical Oncology, Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
14 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Supplementary Table 3: Overview of the six flow cytometry panels.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Supplementary Table 3: Overview of the six flow cytometry panels.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Supplementary Figure 8: Gating strategy for FlowSOM MC17 eosinophils.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Supplementary Figure 8: Gating strategy for FlowSOM MC17 eosinophils.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Supplementary Figure 5: Statistical results for neutrophil-to-lymphocyte ratios (NLRs) at different time points.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Supplementary Figure 5: Statistical results for neutrophil-to-lymphocyte ratios (NLRs) at different time points.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Supplementary Figure 1: Manual gating strategy.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Supplementary Figure 1: Manual gating strategy.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Supplementary Table 4: Overview of used antibodies and catalog numbers.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Supplementary Table 4: Overview of used antibodies and catalog numbers.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Supplementary Figure 2: Data preprocessing overview.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Supplementary Figure 2: Data preprocessing overview.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Immune checkpoint blockade (ICB) therapy has transformed non–small cell lung cancer (NSCLC) treatment and improved overall survival (OS). However, not all patients are responsive. Using computational cytometry analysis to identify immune cell subsets and early dynamic changes, we aimed to unravel the mechanisms underlying diverse responses to ICB in NSCLC. Peripheral blood from 34 patients with NSCLC treated with nivolumab monotherapy was collected at three time points (baseline, week 2, and week 4, referred to as TP1, TP2 and TP3, respectively). Six flow cytometry panels provided comprehensive immune cell profiling, and an R pipeline was designed for data analysis. Differences in abundances, ratios, and functional marker expression were explored in relation to survival. Two additional cohorts were collected and processed similarly. The computational pipeline provided reliable results and is generalizable to new patient cohorts. A decrease in the neutrophil-to-lymphocyte ratio (NLR) between TP2 and TP3 correlated with longer OS. Additionally, patients with an increase in CD8+ T cells between TP2 and TP3 had a higher survival probability. Lastly, we identified a CD11c+ eosinophil subset that increased in patients with a longer OS. Overall, the automated computational approach could be used to analyze clinical multicenter cytometry data in an objective and a reproducible way. Moreover, potential dynamic biomarkers to assess prognosis during ICB therapy in NSCLC were identified, including changes in NLR, CD8+ T cells, and CD11c+ eosinophils. This provides a foundation for further research, emphasizing validation of the pipeline and biomarkers in larger, diverse cohorts and independent datasets to assess their robustness and generalizability.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Immune checkpoint blockade (ICB) therapy has transformed non–small cell lung cancer (NSCLC) treatment and improved overall survival (OS). However, not all patients are responsive. Using computational cytometry analysis to identify immune cell subsets and early dynamic changes, we aimed to unravel the mechanisms underlying diverse responses to ICB in NSCLC. Peripheral blood from 34 patients with NSCLC treated with nivolumab monotherapy was collected at three time points (baseline, week 2, and week 4, referred to as TP1, TP2 and TP3, respectively). Six flow cytometry panels provided comprehensive immune cell profiling, and an R pipeline was designed for data analysis. Differences in abundances, ratios, and functional marker expression were explored in relation to survival. Two additional cohorts were collected and processed similarly. The computational pipeline provided reliable results and is generalizable to new patient cohorts. A decrease in the neutrophil-to-lymphocyte ratio (NLR) between TP2 and TP3 correlated with longer OS. Additionally, patients with an increase in CD8+ T cells between TP2 and TP3 had a higher survival probability. Lastly, we identified a CD11c+ eosinophil subset that increased in patients with a longer OS. Overall, the automated computational approach could be used to analyze clinical multicenter cytometry data in an objective and a reproducible way. Moreover, potential dynamic biomarkers to assess prognosis during ICB therapy in NSCLC were identified, including changes in NLR, CD8+ T cells, and CD11c+ eosinophils. This provides a foundation for further research, emphasizing validation of the pipeline and biomarkers in larger, diverse cohorts and independent datasets to assess their robustness and generalizability.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Supplementary Figure 7: Survival plots for TP3-TP2 delta CD4+ T cells.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Supplementary Figure 7: Survival plots for TP3-TP2 delta CD4+ T cells.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Supplementary Table 2: Overview of the data.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Supplementary Table 2: Overview of the data.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Supplementary Figure 3: Correlation between the percentages obtained by manual gating and our computational pipeline.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade
Supplementary Figure 3: Correlation between the percentages obtained by manual gating and our computational pipeline.